

# Efficacy of aflibercept on exudative age-related macular degeneration in patients exhibiting complete ranibizumab resistance and tachyphylaxis

*Eficácia do aflibercept em pacientes portadores de degeneração macular relacionada à idade exsudativa com resistência completa e taquifilaxia ao ranibizumab*

GOKCEN GOKCE<sup>1</sup>, ALI HAKAN DURUKAN<sup>2</sup>, MEHMET TALAY KOYLU<sup>3</sup>, MURAT KUCUKEVCILIOGLU<sup>2</sup>

## ABSTRACT

**Purpose:** The present study compared the efficacy of aflibercept for neovascular age-related macular degeneration (NV-AMD) in patients with complete ranibizumab resistance and tachyphylaxis.

**Methods:** Forty-four eyes of 38 neovascular age-related macular degeneration patients were evaluated. Eyes were divided into a complete resistance group (n=23 eyes) and tachyphylaxis group (n=21 eyes).

**Results:** After three injections, eight (38.1%) patients in the tachyphylaxis group and nine (39.1%) in the complete resistance group presented with macular dryness. After the first injection of aflibercept, the mean visual acuity improved significantly in the tachyphylaxis group (p=0.018) but remained unchanged in the complete resistance group (p=0.37). There was a non-significant trend towards improved mean visual acuity in both groups after the second and third injections relative to the acuity at the final visit for ranibizumab treatment. In the tachyphylaxis group, the presence of subfoveal pigmented epithelium detachment (PED) decreased significantly after intravitreal aflibercept treatment.

**Conclusions:** Although treatment with aflibercept yielded generally positive anatomical results in both groups, no significant increase in visual acuity was achieved.

**Keywords:** Angiogenesis inhibitors; Macular degeneration; Ranibizumab; Tachyphylaxis; Vascular endothelial growth factor A

## RESUMO

**Objetivo:** O presente estudo comparou a eficácia do aflibercept na degeneração macular neovascular relacionada à idade (NV-AMD) com de resistência completa ao ranibizumab e taquifilaxia ao ranibizumab.

**Método:** Quarenta e quatro olhos de 38 pacientes com degeneração macular neovascular relacionada à idade foram inscritos. Eles foram divididos em dois grupos: grupo de resistência completa (n=23 olhos) e grupo taquifilaxia (n=21 olhos).

**Resultados:** Depois de três injeções, 8 (38,1%) olhos no grupo de taquifilaxia e 9 (39,1%) olhos no grupo de resistência completa, apresentaram mácula seca. Após a primeira injeção de aflibercept, a acuidade visual média melhorou significativamente no grupo taquifilaxia (p=0,018) e manteve-se inalterada no grupo de resistência completa (p=0,37). Houve uma tendência de melhora da acuidade visual média em ambos os grupos após a segunda e terceira injeções em comparação com a última visita do tratamento com ranibizumab, mas isso não foi estatisticamente significativo. A presença de descolamento do epitélio pigmentado subfoveal (PED) em olhos com taquifilaxia ao ranibizumab diminuiu significativamente após o tratamento aflibercept intravítreo.

**Conclusões:** Embora o tratamento com aflibercept tenha mostrado resultados anatômicos positivos em ambos os grupos, não foi obtida melhora significativa da acuidade visual.

**Descritores:** Inibidores de angiogênese; Degeneração macular; Ranibizumab; Taquifilaxia; Fator A de crescimento do endotélio vascular

## INTRODUCTION

The intravitreal administration of vascular endothelial growth factor inhibitors (anti-VEGF) has had positively effects on the visual prognosis of patients with neovascular age-related macular degeneration (AMD). The effectiveness of monthly intravitreal ranibizumab injections was demonstrated previously in the multi-center Marina<sup>(1)</sup> and ANCHOR<sup>(2)</sup> studies. Stable visual acuity has been provided to many patients through monthly or pro-re-nata treatment protocols that were designed around the patient and disease severity<sup>(3)</sup>. However, although many patients achieved positive results at treatment onset, some patients continue to experience macular exudation and progressive vision loss despite receiving repeated injections in subsequent months. The 1- and 2-year results of the CATT study showed that in more than 50% of patients who received ranibizumab treatment, persistent fluid development occurred at the end of month 12<sup>(4,5)</sup>. Patients

in this group, in whom dramatic disease progression was observed, were defined as the treatment-resistant patient group. Although the mechanism of resistance could not be entirely explained, tolerance to ranibizumab and tachyphylaxis are thought to contribute to this situation<sup>(6)</sup>. Although no dosage-related differences in the efficiency of ranibizumab were observed in the Harbor study<sup>(7)</sup>, the SAVE studies<sup>(8,9)</sup> showed that a loss of efficacy could be overcome in some patients by increasing the dosage and administration frequency. However, the remaining patients did not achieve positive results, leading to the clinical outcome of permanent vision loss.

Recently published studies have discussed the effectiveness of intravitreal aflibercept in cases involving insufficient responses to ranibizumab treatment and the development of recurrence and tolerance in subsequent months<sup>(10-20)</sup>. Additional studies have shown that a change of intravitreal agents might be effective in patients with neovascular

Submitted for publication: May 4, 2016

Accepted for publication: July 23, 2016

<sup>1</sup> Department of Ophthalmology, Kayseri Military Hospital, Kayseri, Turkey.

<sup>2</sup> Department of Ophthalmology, Gulhane Military Medical Academy, Ankara, Turkey.

<sup>3</sup> Department of Ophthalmology, Tatvan Military Hospital, Bitlis, Turkey.

**Funding:** No specific financial support was available for this study.

**Disclosure of potential conflicts of interest:** None of the authors have any potential conflicts of interest to disclose.

**Corresponding author:** Gokcen Gokce. Department of Ophthalmology. Kayseri Military Hospital Melikgazi, Kayseri - 38100 Turkey - E-mail: drgokcengokce@gmail.com

**Approved by the following research ethics committee:** Gulhane Military Medical Academy (# 07/2015).

AMD cases who develop tachyphylaxis to anti-VEGFs<sup>(21,22)</sup>. In contrast to previous studies, we aimed to demonstrate the short-term effectiveness of intravitreal aflibercept therapy in patients who had exhibited complete resistance to ranibizumab treatment; in other words, we included patients who were completely non-responsive from the first dose, as well as those who developed tachyphylaxis to ranibizumab. The present study compared these two groups.

## METHODS

This interventional clinical study included 44 eyes of 38 patients with exudative AMD and complete ranibizumab (*Lucentis*<sup>®</sup>, Genentech, Inc., South San Francisco, CA, USA) resistance or ranibizumab tachyphylaxis and subsequently received three aflibercept (*Eylea*<sup>®</sup>, Regeneron, Tarrytown, NY, USA) injections and were followed up for 3 months. This study was conducted in accordance with the tenets of the Declaration of Helsinki, after receiving approval from the institutional ethics review board.

## PATIENT SELECTION

The charts of all patients with exudative AMD who were treated with ranibizumab at the Gulhane Military Medical Academy, Department of Ophthalmology were reviewed, and the above-mentioned patients and eyes were subsequently selected. A diagnosis of exudative AMD was confirmed by fluorescein angiography and optical coherence tomography (OCT). Patients were divided into "complete resistance" (23 eyes) and "tachyphylaxis" groups (21 eyes). Complete ranibizumab resistance was defined as a decrease in the central subfield thickness (CST) of <30  $\mu\text{m}$ , followed by persistent intraretinal and/or subretinal fluid despite monthly injections. Recurrences that responded well to repeated ranibizumab injections were not considered resistant. Ranibizumab tachyphylaxis was defined as an initial decrease of >30  $\mu\text{m}$  in the CST and subretinal fluid after the first injection, followed by a persistent increase in the CST or persistent subretinal fluid on OCT despite repeated injections. Eyes were considered to be completely resistant or tachyphylactic after six monthly ranibizumab injections. The OCT criteria for aflibercept treatment were identical to the ranibizumab re-treatment criteria. Indications for aflibercept treatment included persistent subretinal/intraretinal fluid with or without pigment epithelial detachment (PED).

## INCLUSION CRITERIA

Prior to the initiation of 2 mg/0.05 mL aflibercept therapy, eyes with persistent subfoveal fluid must have received six monthly injections of 0.5-mg ranibizumab. The required interval between the last ranibizumab treatment and first aflibercept treatment was >4 weeks and <6 weeks<sup>(17)</sup>.

## EXCLUSION CRITERIA

Eyes previously treated with photodynamic therapy or intravitreal bevacizumab, eyes with insufficient clinical records or <6 previous ranibizumab injections, eyes with a lack of follow-up after conversion to aflibercept, eyes with macular dryness, eyes that responded well to repeated ranibizumab injections, and eyes with a diagnosis of polypoidal choroidal vasculopathy, retinal angiomatous proliferation, retinal pigment epithelium tear, fibrovascular scarring, or retinal conditions other than exudative AMD were not included in the study.

## MAIN OUTCOME MEASURES

The main outcome measures were the visual and anatomical results at 1 month after the third injection of aflibercept. Best corrected visual acuity (BCVA) was measured using the Snellen visual acuity chart. BCVA values were converted to the logarithm of minimum angle of resolution (logMAR) format for statistical analysis<sup>(23)</sup>. With aflibercept treatment, improvement and worsening were defined as a gain or loss of

$\geq 2$  lines on the Snellen chart. Stabilization was defined as remaining within  $\pm 1$  line of the baseline Snellen result after the last dose of ranibizumab<sup>(18)</sup>. Anatomical changes in CST were classified as a complete resolution or macular dryness (absence of both subretinal and intraretinal fluid on all radial OCT scans), partial resolution, unchanged, or worsening<sup>(18,24)</sup>. Spectral domain OCT images were obtained using a Heidelberg Spectralis OCT (Heidelberg Engineering, Inc., Vista, CA, USA). All measurements were recorded at the baseline and after each intravitreal ranibizumab and aflibercept injection. Calipers were used in instances involving artifacts in the automated measurements. Pigment epithelium detachment (PED) was categorized as present or absent based on a review of subretinal OCT scans.

## STATISTICAL ANALYSIS

Data are presented as means  $\pm$  standard deviations or frequencies. The Shapiro-Wilk test was used to evaluate the normality of measurements. Paired variables before and after aflibercept switching were analyzed using the Wilcoxon signed rank test. Fisher's exact test, the  $\chi^2$  test, and McNemar's test were used to assess categorical variables where appropriate. The Mann-Whitney U test was used to compare improvements between the ranibizumab resistance and tachyphylaxis groups. Improvements were calculated by subtracting pre-treatment data from post-treatment data. All statistical tests were two-tailed, and significance was defined as a p value <0.05. Statistical analyses and graphic production were performed using MedCalc (Version 15.4; MedCalc Software, Ostend, Belgium).

## RESULTS

Among the 23 eyes with complete ranibizumab resistance and 21 eyes with ranibizumab tachyphylaxis, the mean ages at baseline were  $73.4 \pm 10.5$  and  $72.1 \pm 8.8$  years, respectively ( $p=0.54$ ). All eyes received three aflibercept treatments after a series of six ranibizumab injections. None of the studied eyes developed endophthalmitis, sterile inflammation, vitreous hemorrhage, or retinal tears.

## ANATOMIC OUTCOMES WITH AFLIBERCEPT


Figure 1 A shows the changes in mean CST over the study period relative to the baseline values. In both groups, the CST decreased significantly after each injection of aflibercept as compared to the values measured after the last ranibizumab treatment ( $p \leq 0.002$  for all; Figure 2 A, B, C). There was no significant difference between the groups regarding the decrease in CST after each of the three aflibercept injections when compared with the values measured after the last ranibizumab treatment ( $p \geq 0.13$  for all; Figure 3 A).

After three injections, eight (38.1%) of the 21 eyes in the tachyphylaxis group had a dry macula, six (28.6%) had partial resolution of subretinal fluid, three (14.3%) remained unchanged, and four (19%) worsened (Table 1). The mean improvement in CST was 68.4  $\mu\text{m}$  (range: 22-425  $\mu\text{m}$ ,  $p=0.002$ ; Figure 3 A). In 16 of 21 eyes (76.2%), a subfoveal PED was observed at the visit after the last ranibizumab injection. In contrast, a subfoveal PED was observed in six eyes during the visit after the third aflibercept injection (28.6%;  $p=0.002$ ; Figure 4).


After three injections, nine (39.1%) of the 23 eyes in the complete resistance group had a dry macula, nine (39.1%) had partial resolution of subretinal fluid, three (13.0%) remained unchanged, and two (8.7%) worsened (Table 1). The mean improvement in CST was 116.6  $\mu\text{m}$  (range: 45-520  $\mu\text{m}$ ,  $p < 0.001$ ; Figure 3 A). In 10 of the 23 eyes (43.5%), a subfoveal PED was observed at the visit after the last ranibizumab injection. In contrast, a subfoveal PED was observed in seven eyes at the visit after the third aflibercept injection (30.4%;  $p=0.25$ ; Figure 4).

## VISUAL OUTCOMES WITH AFLIBERCEPT

The change in mean BCVA during the study period was compared with the baseline values and is shown in figure 1 B. After the first



A= aflibercept; R= ranibizumab.  
**Figure 1.** Graphs of the changes in visual and anatomical results over time. A) Changes in the central subfield thickness. B) Changes in the best corrected visual acuity.



logMAR= logarithm of the minimum angle of resolution; \* $p < 0.05$ = Wilcoxon signed rank test

**Figure 2.** Scatterplots showing the results after each aflibercept injection relative to those at the last visit after ranibizumab treatment. A) Central subfield thickness (CST) after the first injection. B) CST after the second injection. C) CST after the third injection. D) logMAR visual acuity after the first injection. E) logMAR visual acuity after the second injection. F) logMAR visual acuity after the third injection.

injection of aflibercept, the mean visual acuity improved significantly in the tachyphylaxis group ( $p=0.018$ ) but remained unchanged in the complete resistance group ( $p=0.37$ ; Figure 2 D). There was a trend towards improved mean visual acuity in both groups after the second and third injections when compared to the last visit after ranibizumab treatment, although these improvements were not statistically significant (Figure 2 E, F). There was no significant difference between the groups regarding BCVA improvements after each of the three injections of aflibercept when compared to those at the last visit after ranibizumab treatment ( $p \geq 0.21$  for all; Figure 3B).


After three injections, two (9.5%) of the 21 eyes in the tachyphylaxis group gained  $\geq 2$  Snellen lines, 19 (90.5%) remained stable, and

none (0%) lost  $\geq 2$  Snellen lines (Table 1). The mean increase in the logMAR VA was 0.05 (range: -0.22-0.47,  $p=0.18$ ; Figure 3 B).

After three injections, one (4.3%) of 23 eyes in the complete resistance group gained  $\geq 2$  Snellen lines, 21 (91.4%) remained stable, and one (4.3%) lost  $\geq 2$  Snellen lines (Table 1). The mean gain in the logMAR VA was -0.013 (range: -1.20-0.69,  $p=0.72$ ; Figure 3 B).


## DISCUSSION

For patients with neovascular AMD who achieved an insufficient clinical response despite receiving a suitable treatment dosage, the response to a second anti-VEGF agent differs from patient to patient.



Mann-Whitney U test.

**Figure 3.** Graphs showing the visual and anatomical improvements following each aflibercept injection relative to the values at the last visit after ranibizumab treatment. A) Improvements in the central subfield thickness. B) Improvements in the best corrected visual acuity.



A= aflibercept; R= ranibizumab; p<0.05= McNemar's test.

**Figure 4.** Pigment epithelium detachment distribution over time.

Variable resistance mechanisms among patients comprise an important cause of these differences<sup>(11)</sup>. According to a previous report, 2% of patients receiving treatment for neovascular AMD will develop ranibizumab tachyphylaxis<sup>(22)</sup>. In published studies, tachyphylactic, tolerant, and recurrent cases are generally considered resistant. In tachyphylaxis, which differs from tolerance and recurrence, subretinal fluid is maintained or increases despite recurring intravitreal injections<sup>(22)</sup>. Therefore, cases wherein visual stabilization is achieved through intravitreal treatment and wherein the CST has not changed are not considered to be solely tachyphylactic<sup>(21,22)</sup>. Tachyphylaxis is believed to be caused by the acute development of antibodies against anti-VEGF agents, and usually occurs after the first dose. It is also believed that while receiving ranibizumab treatment, which has a specific affinity for VEGF-A, an alternative, VEGF-B-dependent angiogenic process affects the development of tachyphylaxis<sup>(25)</sup>. The high affinity of aflibercept for both VEGF-A and VEGF-B could therefore explain the effectiveness of this agent in tachyphylactic cases. Although no studies have selectively investigated such cases, Hariri et al. very recently published the results of a short-term investigation of intravitreal aflibercept in cases exhibiting resistance to intravitreal ranibizumab and bevacizumab. These authors observed

**Table 1.** Distributions of visual and anatomical improvements following each aflibercept injection relative to the values after the last ranibizumab treatment

Final outcome measures	Ranibizumab tachyphylaxis (n=21)	Complete resistance (n=23)	P value
<b>Best corrected visual acuity</b>			
After 1 <sup>st</sup> aflibercept injection n (%)			
Gaining two snellen lines	2 ( 9.5)	0 (0)	0.22 <sup>a</sup>
Gaining one snellen line	5 (23.8)	5 (21.7)	1.00 <sup>a</sup>
Unchanged	14 (66.7)	14 (60.9)	0.69 <sup>b</sup>
Losing one snellen line	0 (0)	3 (13.0)	0.23 <sup>a</sup>
Losing two snellen lines	0 (0)	1 ( 4.3)	1.00 <sup>a</sup>
After 2 <sup>nd</sup> aflibercept injection			
Gaining two snellen lines	2 ( 9.5)	1 ( 4.3)	0.59 <sup>a</sup>
Gaining one snellen line	6 (28.6)	6 (26.1)	0.85 <sup>b</sup>
Unchanged	10 (47.6)	12 (52.2)	0.76 <sup>b</sup>
Losing one snellen line	3 (14.3)	2 ( 8.7)	0.65 <sup>a</sup>
Losing two snellen lines	0 (0)	2 ( 8.7)	0.48 <sup>a</sup>
After 3 <sup>rd</sup> aflibercept injection			
Gaining two snellen lines	2 ( 9.5)	1 ( 4.3)	0.59 <sup>a</sup>
Gaining one snellen line	7 (33.3)	7 (30.4)	0.83 <sup>b</sup>
Unchanged	9 (42.9)	10 (43.5)	0.96 <sup>b</sup>
Losing one snellen line	3 (14.3)	4 (17.4)	1.00 <sup>a</sup>
Losing two snellen lines	0 (0)	1 ( 4.3)	1.00 <sup>a</sup>
<b>Central subfield thickness</b>			
After 1 <sup>st</sup> aflibercept injection n (%)			
Dry macula	6 (28.6)	5 (21.7)	0.60 <sup>b</sup>
Partial resolution	7 (33.3)	10 (43.5)	0.49 <sup>b</sup>
Unchanged	6 (28.6)	5 (21.7)	0.60 <sup>b</sup>
Worse	2 ( 9.5)	3 (13.0)	1.00 <sup>a</sup>
After 2 <sup>nd</sup> aflibercept injection n (%)			
Dry macula	8 (38.1)	8 (34.8)	0.82 <sup>b</sup>
Partial resolution	5 (23.8)	9 (39.1)	0.27 <sup>b</sup>
Unchanged	4 (19.0)	4 (17.4)	1.00 <sup>a</sup>
Worse	4 (19.0)	2 (08.7)	0.40 <sup>a</sup>
After 3 <sup>rd</sup> aflibercept injection n (%)			
Dry macula	8 (38.1)	9 (39.1)	0.94 <sup>b</sup>
Partial resolution	6 (28.6)	9 (39.1)	0.46 <sup>b</sup>
Unchanged	3 (14.3)	3 (13.0)	1.00 <sup>a</sup>
Worse	4 (19.0)	2 ( 8.7)	0.40 <sup>a</sup>

<sup>a</sup>= Fisher's exact test (two-sided); <sup>b</sup>= Pearson chi-square test.

stabilization or recovery of the subretinal fluid in 87% of the cases<sup>(26)</sup>. Similarly, our study observed corresponding rates of 81% in the tachyphylaxis group and 91.3% in the complete resistance group.

In our study, visual acuity stabilization was achieved in 90.5% and visual acuity increased in 9.5% of eyes with ranibizumab tachyphylaxis after three doses of aflibercept injections; among eyes with complete resistance to ranibizumab, visual acuity stabilization was observed in 91.4% and visual acuity was increased in 4.3%. These functional results were similar to those of a retrospective study by Ho et al. in which the importance of tachyphylaxis in resistance was emphasized using an average of 2.6 aflibercept injections that provided visual stabilization in 85% and increased visual acuity in 7% of eyes<sup>(18)</sup>. That study also observed full resolution of subretinal/intraretinal fluid in 35-42% of the eyes and a partial response in 18-25% of the eyes; the corresponding results in our study were found to be 38.1% and 23.8% in the tachyphylaxis group, respectively, and 39.1% and 39.1% in the complete resistance group, respectively. Although the anatomical and functional results of our study were similar to those reported by Ho et al., the latter study involved cases resistant to bevacizumab as well as those resistant to ranibizumab, and the previous average injection amounts varied rather widely; in other words, our study was more homogeneous.

In our study, CST decreased in 66.7% of the tachyphylaxis group and 78.2% of the complete resistance group after three aflibercept injections. These results were lower than the 91% decrease observed in a 4-month retrospective study of 68 ranibizumab-resistant eyes conducted by Yonekawa et al.<sup>(20)</sup>. However, the increase in visual acuity at the end follow-up in that study was not statistically significant, similar to the results of our study.

In our study, the decreases in CST at the end of 3 months were 68.4  $\mu$ m in the tachyphylaxis group and 116.6  $\mu$ m in the complete resistance group. These amounts were similar to the 89.4- $\mu$ m decrease observed in a prospective 6-month study of a similar patient cohort by Chang et al., and the 87.2- $\mu$ m decrease observed in a retrospective 6-month study by Kumar et al.<sup>(3,16)</sup>. In the study by Chang et al., an increase in visual acuity of  $\geq 1$  Snellen line was detected in 55% of the eyes at 6 months; in our study, the corresponding rates at the end of 3 months were 42.8% in the tachyphylaxis group and 34.7% in the complete resistance group. Notably, the increase in visual acuity observed by Chang et al. at the end of a 6-month follow-up was statistically significant, whereas in our study, the change at the end of 3 months was not significant. Kumar et al. observed a statistically significant average change of 0.02 logMAR at the end of the follow-up period, whereas in our study the corresponding rates were 0.05 logMAR in the tachyphylaxis group and -0.01 logMAR in the complete resistance group. This difference was not statistically significant. However, the different natures, follow-up periods, numbers of injections, and patient groups of these studies might have led to similar rates with statistical variation.

A retrospective study by Arcinue et al., one of the most recent studies on this subject, observed an average visual acuity increase of 0.05 logMAR together with a dry macula in 60.3% of the eyes at the end of 6 months<sup>(15)</sup>. Additionally, visual acuity remained unchanged in 38.1% of the eyes, an increase of  $\geq 1$  line was observed in 36.5% of the eyes, and a decrease of  $\geq 1$  line was observed in 23.8% of the eyes. In contrast, in our study, the dry macula and unchanged, increased, and decreased visual acuity rates at 3 months after the aflibercept injections were 38.1%, 42.9%, 42.8%, and 14.3%, respectively, in the tachyphylaxis group, and 39.1%, 43.5%, 34.7%, and 21.7%, respectively, in the complete resistance group. The high rate of dry macula in the study by Arcinue et al. can be largely attributed to the inclusion of both recurrent and persistent cases in the working group<sup>(15)</sup>.

Studies have shown that intravitreal aflibercept injections are also effective against other anti-VEGF resistant PEDs<sup>(3,27)</sup>. In this regard, Singh et al. conducted the prospective ASSESS study, which included a follow-up period of 12 months; at the end of 6 months, PED regression

was observed in 19.2% of the studied eyes<sup>(19)</sup>. In our study, at the end of 3 months, PED had completely regressed in 13.1% of the eyes that were completely resistant to ranibizumab; in addition, the very high PED regression rate of 47.6% in the tachyphylaxis group was one of the most significant findings of our study. As specifically noted in the ASSESS study, a change in the intravitreal agent yields a much higher anatomic response among patients who have developed anti-VEGF resistance than in other patient groups because of tachyphylaxis<sup>(19)</sup>. However, given the various issues with the identification of patients who develop tachyphylaxis in isolation, such differences in response are difficult to determine selectively<sup>(19)</sup>. Consequently, our results are very important because this is the first study to selectively evaluate eyes with ranibizumab tachyphylaxis and eyes with complete resistance to ranibizumab, which were not grouped in previous studies. In addition, similar to the previous studies in the literature, we observed a disagreement between anatomic and functional improvements. This discrepancy can be attributed to the loss of photoreceptors and functional losses in the subretinal area during the early period of the disease<sup>(11)</sup>. Studies with much longer terms and those that include only tachyphylactic patients are needed to determine whether this positive anatomic effect of intravitreal aflibercept injection would be maintained during a longer follow-up, particularly in the ranibizumab tachyphylaxis group.

This study had some limitations. We note that the study design, short follow-up term, and relatively small sample might have influenced our results. In addition, Snellen and logMAR are not the best options for BCVA measurement in retinal studies. Rather, ETDRS letters should be used. Although a diagnosis of tachyphylaxis is mainly based on clinical observations, some patients who develop tachyphylaxis may produce specific antibodies. However, because it is impossible to identify these antibodies in every patient and the antibody type cannot usually be isolated as a result of morphological variety, it was deemed more appropriate to evaluate tachyphylaxis cases clinically rather than via laboratory testing. Further, it is quite challenging to plan a prospective selection process that involves tachyphylaxis cases because although the development of tachyphylaxis can be observed over time, we cannot predict which patients will develop this condition. Tachyphylaxis may also develop after subsequent doses of ranibizumab, rather than after the first dose. However, patients in whom tachyphylaxis developed later in the treatment course were not included in our study because such cases might not be accurately differentiated from recurrence or tolerance.

In conclusion, our study revealed that intravitreal aflibercept treatment yielded a statistically significant decrease in the short-term CST in eyes that were non-responsive to ranibizumab, as well as in eyes that had developed tachyphylaxis to ranibizumab. However, although positive results were observed in both groups, no statistically significant increase in visual acuity was achieved. The presence of subfoveal PED in eyes with ranibizumab tachyphylaxis decreased significantly after intravitreal aflibercept treatment. Studies with longer durations are needed to determine whether this positive effect of intravitreal aflibercept injection on tachyphylaxis and full resistance would be maintained in the long-term.

## REFERENCES

1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. *N Engl J Med.* 2006;355(14):1419-31. Comment in: *N Engl J Med.* 2006;355(14):1409-12; *N Engl J Med.* 2007;356(7):748-9. *N Engl J Med.* 2007;356(7):747-8/ author reply 740-50. *N Engl J Med.* 2006;355(14):1493-5.
2. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. *Ophthalmology.* 2009; 116(1):57-65 e5. Comment in: *Ophthalmology.* 2009;116(8):1593.
3. Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, et al. Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. *Retina.* 2013;33(8):1605-12.

4. CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. *N Engl J Med.* 2011;364(20):1897-908. Comment in: *N Engl J Med.* 2011;364(20):1966-7; *N Engl J Med.* 2011;365(23):2238; *N Engl J Med.* 2011;365(23):2237; author reply 2237. *JAMA.* 2014;311(15):1491-2; *Clin Experiment Ophthalmol.* 2011;39(7):718-20.
5. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research G, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. *Ophthalmology.* 2012;119(7):1388-98. Comment in: *J Comp Eff Res.* 2012;1(6):485-8; *JAMA Ophthalmol.* 2015;133(3):363-4. *JAMA Ophthalmol.* 2015;133(6):726.
6. Binder S. Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? *Br J Ophthalmol.* 2012;96(1):1-2. Comment in: *Br J Ophthalmol.* 2012;96(1):21-3. *Br J Ophthalmol.* 2012;96(1):14-20.
7. Busbee BG, Ho AC, Brown DM, Heier JS, Suner IJ, Li Z, Rubio RG, Lai P; HARBOR Study Group. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. *Ophthalmology.* 2013;120(5):1046-56.
8. Wykoff CC, Brown DM, Croft DE, Wong TP. Two Year SAVE Outcomes: 2.0 mg ranibizumab for recalcitrant neovascular AMD. *Ophthalmology.* 2013;120(9):1945-6 e1.
9. Wykoff CC, Brown DM, Chen E, Major JC, Croft DE, Mariani A, Wong TP; SAVE Study Group. SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results. *Ophthalmic Surg Lasers Imaging Retina.* 2013;44(2):121-6. *Ophthalmic Surg Lasers Imaging Retina.* 2013;44(2):109.
10. Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi MP, Shi E, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. *Angiogenesis.* 2012;15(2):171-85.
11. Bakall B, Folk JC, Boldt HC, Sohn EH, Stone EM, Russell SR, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. *Am J Ophthalmol.* 2013;156(1):15-22 e1.
12. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, Kirchhof B, Ho A, Ogura Y, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Groetzbach G, Sommerauer B, Sandbrink R, Simader C, Schmidt-Erfurth U; VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. *Ophthalmology.* 2012;119(12):2537-48. Erratum in: *Ophthalmology.* 2013;120(1):209-10.
13. Ogura Y, Terasaki H, Gomi F, Yuzawa M, Iida T, Honda M, Nishijo K, Sowade O, Komori T, Schmidt-Erfurth U, Simader C, Chong V; VIEW 2 Investigators. Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration: outcomes in the Japanese subgroup of the VIEW 2 study. *Br J Ophthalmol.* 2015;99(1):92-7.
14. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. *Ophthalmology.* 2014;121(1):193-201.
15. Arcinieg CA, Ma F, Barteselli G, Sharpsten L, Gomez ML, Freeman WR. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. *Am J Ophthalmol.* 2015;159(3):426-36 e2. Comment in: *Am J Ophthalmol.* 2015;159(5):996-7.
16. Chang AA, Li H, Broadhead GK, Hong T, Schlub TE, Wijeyakumar W, et al. Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. *Ophthalmology.* 2014;121(1):188-92.
17. Gharbiya M, Iannetti L, Parisi F, De Vico U, Mungo ML, Marenco M. Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. *BioMed Res Int.* 2014;2014:273754.
18. Ho VY, Yeh S, Olsen TW, Bergstrom CS, Yan J, Cribbs BE, et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. *Am J Ophthalmol.* 2013;156(1):23-8 e2.
19. Singh RP, Srivastava S, Ehlers JP, Bedi R, Schachat AP, Kaiser PK. A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis. *Br J Ophthalmol.* 2014;98 Suppl 1:i22-7.
20. Yonekawa Y, Andreoli C, Miller JB, Loewenstein JI, Sobrin L, Elliott D, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. *Am J Ophthalmol.* 2013;156(1):29-35 e2.
21. Gasperini JL, Fawzi AA, Khondkaryan A, Lam L, Chong LP, Elliott D, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. *Br J Ophthalmol.* 2012;96(1):14-20. Comment in: *Br J Ophthalmol.* 2012;96(1):1-2.
22. Egho MS, Sorensen TL. Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. *Br J Ophthalmol.* 2012;96(1):21-3. Comment in: *Br J Ophthalmol.* 2012;96(1):1-2.
23. Holladay JT. Visual acuity measurements. *J Cataract Refract Surg.* 2004;30(2):287-90.
24. Ijiri S, Sugiyama K. Short-term efficacy of intravitreal aflibercept for patients with treatment-naive polypoidal choroidal vasculopathy. *Graefes Arch Clin Exp Ophthalmol.* 2015;253(3):351-7.
25. Miura M, Iwasaki T, Goto H. Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis. *Clin Ophthalmol.* 2013;7:1591-5.
26. Hariri A, Diniz B, Fou LV, Lam LA, Nittala MG, Sadda SR. Quantitative OCT subanalysis of eyes with choroidal neovascularization switched from multiple injections of bevacizumab or ranibizumab to intravitreal aflibercept. *Ophthalmic Surg Lasers Imaging Retina.* 2015;46(2):195-200.
27. Broadhead GK, Hong T, Zhu M, Li H, Schlub TE, Wijeyakumar W, et al. Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration. *Retina.* 2015;35(5):975-81.